MVASI® is a vascular endothelial growth factor inhibitor indicated for the treatment of: MVASI®, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic colorectal cancer (mCRC).... Read More
Amgen Assist 360™
Whether you need insurance verification, co-pay and reimbursement resources, or would like to talk to an Amgen Field Reimbursement Specialist, we’re here for you.
CALL
1-888-4ASSIST
(1-888-427-7478)
Monday to Friday
9:00 am to 8:00 pm ET
or visit
AmgenAssist360.com.
AMGEN REIMBURSEMENT COUNSELORS
Connect with an Amgen Reimbursement Counselor or schedule a visit with a Field Reimbursement Specialist.
PATIENT RESOURCE GUIDE
Find co-pay and reimbursement resources* for patients with different kinds of insurance, or no insurance at all.
BENEFIT VERIFICATION
Submit, store, and retrieve benefit verifications for all your patients currently on an Amgen product.
To enroll your patients in the Amgen FIRST STEP™ Program, please call 1-888-65-STEP1 (1-888-657-8371) or visit AmgenFIRSTSTEP.com.
The Amgen FIRST STEP™ Program
can help your eligible commercially insured patients cover their out-of-pocket prescription costs, including deductible, co-insurance, and
co-payment.†
AMGEN ASSIST 360™: HELPING YOUR PATIENTS FIND RESOURCES IMPORTANT TO THEM
*Resources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits’ criteria. Amgen has no control over these programs and provides referrals as a courtesy only.
†Terms, conditions, and program maximums apply. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.
Serious adverse reactions (Warnings and Precautions)
Pregnancy warning
Most common adverse reactions
Indication-specific adverse reactions
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch.
You may also report side effects to Amgen at 1-800-772-6436.
Please see full Prescribing Information for additional Important Safety Information.
INDICATIONS
MVASI® is a vascular endothelial growth factor inhibitor indicated for the treatment of:
MVASI®, in combination with intravenous fluorouracil-based chemotherapy, is indicated for the first- or second-line treatment of patients with metastatic colorectal cancer (mCRC).
MVASI®, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy, is indicated for the second-line treatment of patients with mCRC who have progressed on a first-line bevacizumab product-containing regimen.
Limitations of Use: MVASI® is not indicated for adjuvant treatment of colon cancer.
MVASI®, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC).
MVASI® is indicated for the treatment of recurrent glioblastoma (GBM) in adults.
MVASI®, in combination with interferon-alfa, is indicated for the treatment of metastatic renal cell carcinoma (mRCC).
MVASI®, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer (CC).
MVASI®, in combination with carboplatin and paclitaxel, followed by MVASI® as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection (OC).
MVASI®, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens (OC).
MVASI®, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by MVASI® as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (OC).
MVASI® Important Safety Information
Serious adverse reactions (Warnings and Precautions)